Cargando…

The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer

SIMPLE SUMMARY: Disease recurrence and chemotherapy resistance are the major causes of mortality for the majority of epithelial ovarian cancer (EOC) patients. Standard of care relies on cytotoxic drugs that induce a form of cell death called apoptosis. EOC cells can evolve to resist apoptosis. We de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nachtigal, Mark W., Altman, Alon D., Arora, Rajat, Schweizer, Frank, Arthur, Gilbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322924/ https://www.ncbi.nlm.nih.gov/pubmed/35884379 http://dx.doi.org/10.3390/cancers14143318

Ejemplares similares

Cytotoxic capacity of a novel glycosylated antitumor ether lipid in chemotherapy-resistant high grade serous ovarian cancer in vitro and in vivo
por: Nachtigal, Mark W, et al.
Publicado: (2021)

Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells
por: Moraya, Amani I., et al.
Publicado: (2017)

Ubiquitin Proteasome Pathway Transcriptome in Epithelial Ovarian Cancer
por: Vriend, Jerry, et al.
Publicado: (2021)

Syntheses of l-Rhamnose-Linked Amino Glycerolipids and Their Cytotoxic Activities against Human Cancer Cells
por: Ogunsina, Makanjuola, et al.
Publicado: (2020)

Exploring Antibiotic-Potentiating Effects of Tobramycin–Deferiprone Conjugates in Pseudomonas aeruginosa
por: Gandhi, Karan, et al.
Publicado: (2023)

The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples
por: Penner-Goeke, Signe, et al.
Publicado: (2017)

Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019
por: Winchar, Kelcey, et al.
Publicado: (2022)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

Expression of resistance gene and prognosis of chemotherapy in primary epithelial ovarian cancer
por: Yang, Fengmei, et al.
Publicado: (2018)

The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer
por: Zhou, Yingying, et al.
Publicado: (2015)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
por: Spanakis, Marios, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

CCNE1 Amplification as a Predictive Biomarker of Chemotherapy Resistance in Epithelial Ovarian Cancer
por: Gorski, Justin W., et al.
Publicado: (2020)

Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer
por: Feng, Li-yuan, et al.
Publicado: (2020)

Primary culture and mRNA analysis of human ovarian cells
por: Dunfield, Lesley D., et al.
Publicado: (2002)

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
por: Kim, Myung Joo, et al.
Publicado: (2012)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer
por: Wang, Lishuang, et al.
Publicado: (2015)

Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis
por: Li, Yuan, et al.
Publicado: (2023)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Mechanisms of chemotherapy resistance in ovarian cancer
por: Ortiz, Mylena, et al.
Publicado: (2022)

High Expression of Lewis y Antigen and CD44 Is Correlated with Resistance to Chemotherapy in Epithelial Ovarian Cancers
por: Hu, Zhenhua, et al.
Publicado: (2013)

Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer
por: Yu, Wen, et al.
Publicado: (2019)

Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway
por: Gao, Yan, et al.
Publicado: (2020)

Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma
por: Zhang, Kai, et al.
Publicado: (2020)

Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
por: Österberg, Lovisa, et al.
Publicado: (2009)

Paraneoplastic myositis secondary to poorly differentiated serous carcinoma of ovarian/tubal origin
por: Raizman, Zachary, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
por: Baruah, Upasana, et al.
Publicado: (2015)

Hyperthermic intraoperative thoracoabdominal chemotherapy for stage IVB epithelial ovarian carcinoma
por: Brind'Amour, Alexandre, et al.
Publicado: (2020)

Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents
por: Maristany, Sumiko, et al.
Publicado: (2022)

Chemotherapy Resistance in Advanced Ovarian Cancer Patients
por: Pokhriyal, Ruchika, et al.
Publicado: (2019)

Biological Insights into Chemotherapy Resistance in Ovarian Cancer
por: Glasgow, Michelle A., et al.
Publicado: (2019)

Response to microtubule-interacting agents in primary epithelial ovarian cancer cells
por: Pellicciotta, Ilenia, et al.
Publicado: (2013)

Guanidinylated Polymyxins as Outer Membrane Permeabilizers Capable of Potentiating Rifampicin, Erythromycin, Ceftazidime and Aztreonam against Gram-Negative Bacteria
por: Ramirez, Danzel Marie, et al.
Publicado: (2022)

Potential of Osteopontin in the Management of Epithelial Ovarian Cancer
por: Cerne, Katarina, et al.
Publicado: (2019)

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2017)

Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer
por: Yoon, Ji-Young, et al.
Publicado: (2014)

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
por: Škof, Erik, et al.
Publicado: (2016)

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
por: Zeng, Long-Jia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_415upcrk2l89pp9urar95kpmbl